Feature | May 16, 2013

Multiple Studies Show Promise for Innovative FIRM Rotor Mapping Method

New mapping method could greatly improve and shorten AFib ablation procedures, but debate persists over question of rotor mobility

May 16, 2013 — New research presented at Heart Rhythm 2013 continues to show promising results for focal impulse and rotor modulation (FIRM) mapping to effectively target atrial fibrillation (AF) sources and improves ablation therapy outcomes. The novel diagnostic real-time mapping system helps target ablation therapy to patient-specific drivers of AF rather than to anatomical targets, which can improve patient outcomes.

More than 2 million people in the United States have AF, a common heart rhythm disorder which causes an irregular and rapid heartbeat. Although it is not life threatening, AF can lead to other problems including chronic fatigue, congestive heart failure and stroke.

“This new procedure has the potential to dramatically change how we treat patients with atrial fibrillation,” said Vijay Swarup, M.D., FHRS, director of cardiac electrophysiology at Arizona Heart Hospital. “New findings help us better understand that small electrical spinning tops – rotors – or focal sources drive AF, the stability of these sources and exactly where to treat them.”

New research builds on the CONFIRM trial findings from 2011 that first showed AF was acutely terminated or substantially slowed with less than 10 minutes of FIRM-guided ablation per identified source.

A new study, led by Robert Kowal, M.D., and presented at Heart Rhythm 2013, provides more information on how FIRM-guided ablation effectively treats AF. FIRM mapping was performed in 210 patients at 11 U.S. centers. Ablation was targeted prospectively at rotors or focal sources in 132 consecutive patients, of whom 25 percent had paroxysmal AF and 75 percent had persistent AF. FIRM-guided ablation achieved an acute endpoint in 82.9 percent of patients with ten minutes of total ablation. This included terminating AF and rendering it noninducible in 55.8 percent of patients, in whom the majority (69 percent) terminated to sinus rhythm and 31 percent terminated to atrial tachycardia.

A second study, led by Swarup, used FIRM to map where electrical rotors or focal sources are located in the heart and found that sources exist in diverse stable locations throughout the atria. The 11-multicenter prospective trial mapped AF in 210 consecutive patients, of whom 132 had FIRM-guided ablation at rotor or focal sources of AF. Sources were revealed in 99.2 percent of patients, and more than half of the AF sources were located away from pulmonary veins. These results further confirm the importance of mapping AF sources in each patient compared to traditional pulmonary vein isolation therapy. In FIRM guided patients, AF termination or 10 percent slowing was achieved.

FIRM rotor mapping has spurred some debate in EP because it is believed by some that these rotors move. If they are stationary, the ablations can be very successful, but if they move, as some believe, relief from AF might only be temporary following a FIRM procedure. 

For more information: www.HRSonline.org

Related Content

Acutus Medical, AcQMap High Resolution Imaging and Mapping System, improvement over sCT

Image courtesy of Acutus Medical

News | EP Mapping and Imaging Systems| October 06, 2015
Acutus Medical, a global heart rhythm technology company, presented data that show the AcQMap High Resolution Imaging...
News | Heart Failure| October 02, 2015
Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the...
AtriCure, cryoFORM cryoablation probe, launch
Technology | Ablation Systems| October 02, 2015
AtriCure Inc. launched the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety...
predicting arrhythmias, mcgill university, alternans patterns
News | EP Lab| September 28, 2015
Researchers have discovered how to predict some cardiac arrhythmias several steps before they even occur. It’s a...
ACC, atrial fibrillation registries, ablation, left atrial appendage occlusion procedures, LAAO Registry
News | Atrial Fibrillation| September 24, 2015
The American College of Cardiology (ACC) launched two new clinical registry programs in August to track real-world...
Biotronik, NORDIC ICD trial, defibrillation testing, DF testing, shock efficacy
News | Implantable Cardioverter Defibrillators (ICD)| September 24, 2015
Biotronik announced the publication of NORDIC ICD (NO Regular Defibrillation testing In Cardioverter-Defibrillator...
guideline, treating supraventricular tachycardia, ACC, AHA, HRS
News | EP Lab| September 23, 2015
A new guideline aimed at helping clinicians treat patients with supraventricular tachycardia, or a rapid heart rate,...
MedLumics, OCT, real-time assessment, catheter ablation, atrial fibrillation
Feature | EP Mapping and Imaging Systems| September 17, 2015
MedLumics has announced the completion of a successful single-case pre-clinical feasibility study of its optical...
Texas Cardiac Arrhythmia Institute, TCAI, first in United States, EpiAccess System, epicardial ablation

Image courtesy of EpiEP

News | Ablation Systems| September 15, 2015
The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first facility in the...
Medtronic, Evera, ICD, MR-conditional, MRI, FDA approval
Technology | Implantable Cardioverter Defibrillators (ICD)| September 14, 2015
Medtronic received the first U.S. Food and Drug Administration (FDA) approval for an implantable cardioverter...
Overlay Init